Home>Topics>Stocks>Nektar Therapeutics

Nektar Therapeutics NKTR

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
    1. CORRECTED-FDA approves AstraZeneca, Nektar constipation drug


      Tue, 16 Sep 2014

      Sept 16 (Reuters) - The U.S. Food and Drug Administration approved an oral therapy to treat opioid-induced constipation developed by Nektar Therapeutics and AstraZeneca Plc .

    2. FDA clears OIC drug


      Tue, 16 Sep 2014

      The FDA approves Nektar Therapeutics ' ( NKTR -0.1% ) Movantik ( naloxegol ) for the treatment of patients with opioid-induced constipation who take opioids for the management

    3. Vectura Group Following A Familiar Path


      Sat, 13 Sep 2014

      By Stephen Simpson, CFA : Investors who like Nektar Therapeutics (NASDAQ: NKTR ) or Alkermes (NASDAQ: ALKS ) may want to take a look at Britain's Vectura Group plc (OTC: VEGPF ) (VEC.L). Although

    4. Nektar 181 Could Dominate A $13B Chronic Pain Market


      Tue, 26 Aug 2014

      By Scrying Biotech : Chronic pain suppression in the U.S. is a $13B market annually whose landscape is constantly changing based upon the unintended consequences of drug addiction. The most popular of these opiates is Purdue's OxyContin, ranked 18th in total U.S. sales last year at $2.46B. Sales of

    5. Nektar Therapeutics Has More To Give


      Thu, 21 Aug 2014

      develop broad pipelines have fared a little better. Nektar Therapeutics (NASDAQ: NKTR ) belongs on that list, as the company continues ..... Nektar's PEGylated naloxol (also known as NKTR -118) has less than a month to go before it should

    6. 2nd Half Of 2014 Biotechnology Catalysts - Part 4


      Sun, 17 Aug 2014

      By Alexander Maxwell : Having previously updated the investment community in part 3 of my Biotechnology Catalysts series, the purpose of this article is to help give investors an idea of the upcoming biotechnology catalysts through the end of September. It can be hard for investors to be able to ...

    7. PDUFA date set for Relistor


      Mon, 11 Aug 2014

      bromide) for treatment of opioid-induced constipation. Salix successfully appealed a CRL that the agency issued on July 27, 2012. Related tickers: (NASDAQ: PGNX ) (NASDAQ: NKTR ) (NYSE: AZN ) (NASDAQ: CBST ) Post your comment!

    8. Nektar Therapeutics Harnesses The Power Of AstraZeneca To Move Movantik


      Thu, 7 Aug 2014

      By Scrying Biotech: Nektar (NASDAQ: NKTR ) Therapeutics of San Francisco has been a hybrid commercial and developmental-stage biotechnology company for many years now

    9. Nektar Therapeutics pain drug for knee arthritis fails study


      Thu, 26 Sep 2013

      (Reuters) - Nektar Therapeutics said its experimental drug to treat chronic pain in patients with arthritis of the knee failed to meet its main goal in a mid-stage clinical trial.

    10. OGICX Oppenheimer Global Opportunities C Fund Analysis, Report, Research, 5 Star Rating – Morningstar

      Fund Reports

      Wed, 2 Nov 2011

      one of the fund's struggling top positions-- Nektar Therapeutics NKTR --slid even further in the downdraft. Several ..... patches. Jennings has held on to top positions in Nektar Therapeutics and Advanced Micro Devices AMD through thick and

    « Prev123Next »
    Content Partners